Nexalin Technology, Inc. develops non-invasive neurostimulation products based on Deep Intracranial Frequency Stimulation, or DIFS™, for brain-health and mental-health indications. Company news commonly covers peer-reviewed clinical publications, neuroimaging and biomarker data, and research programs addressing insomnia, depression, traumatic brain injury, PTSD, Alzheimer’s disease, dementia-related cognitive decline and ADHD.
Updates also describe the HALO™ Clarity device, the NeuroCare® virtual clinic platform, collaborations with clinical research and academic organizations, FDA engagement, and capital-market communications tied to its Nasdaq-listed common stock.
Nexalin Technology, Inc. has successfully closed its initial public offering of 2,315,000 units, each unit comprising one share of common stock and one warrant, at an offering price of $4.15 per unit. This translates to gross proceeds of approximately $9.6 million before expenses. Trading commenced on The Nasdaq Capital Market under the symbols ‘NXL’ for shares and ‘NXLIW’ for warrants on September 16, 2022. The company has also granted underwriters a 45-day overallotment option for additional securities.
Nexalin Technology announced its initial public offering of 2,315,000 units, priced at $4.15 each, aiming to raise approximately $9.6 million. Each unit consists of one common share and one warrant to purchase an additional share at the same price. The units will trade on Nasdaq under the symbols NXL and NXLIW, starting September 20, 2022. Underwriters have a 45-day option for additional shares. The offering is part of Nexalin's strategy to combat mental health issues using its innovative neurostimulation products, including the newly approved Generation 2 device in China.